The exponential growth in scientific publications and major guidelines over the last 6 years on familial hypercholesterolaemia (FH) 1,2 underscores the evolving importance of this condition in preventative cardiology. Ultimately, these works aim to improve outcomes for patients and families by enhancing existing models of care for FH.
1
The exponential growth in scientific publications and major guidelines over the last 6 years on familial hypercholesterolaemia (FH) 1, 2 underscores the evolving importance of this condition in preventative cardiology. Ultimately, these works aim to improve outcomes for patients and families by enhancing existing models of care for FH. [3] [4] [5] The typical model of care for FH has several components: screening and detection of cases; use of diagnostic tools including genetic testing; risk stratification of cases; definition of low-density lipoprotein (LDL) cholesterol targets and their attainment with therapies; organisation of services; utilisation of patient networks and advocacy groups; disease c1odification and registries; development of research programs that can feedback on care. The review by Pec´in et al. 2 summarises recent advances in the management of FH, with a focus on PCSK9 inhibitors that inform evolving models of care. However, certain aspects need underscoring to draw attention to evidence gaps. 1 
Screening and detection
Several population studies have demonstrated that the frequency of heterozygous FH is two-fold greater than previously perceived. [6] [7] [8] FH has accordingly become a public health problem. A geographical survey, however, indicates that apart from the Netherlands and Norway, FH remains largely undiagnosed and untreated. 9 Multiple approaches to detecting cases have been proposed, with selective, opportunistic, systematic and universal strategies all having merits. 3, 10 The greatest yield in detection may be amongst patients with premature coronary disease in coronary care or rehabilitation units, 11, 12 coupled with cascade screening of first-degree relatives, but complementary approaches are required. 3, 5 Cascade testing employing genetic testing has been consistently demonstrated to be costeffective. 13, 14 In primary care, laboratory report alerts on the possibility of FH and bioinformatic tools applied to electronic medical records can prove highly effective. 3, 10 However, this needs to be coupled with a systematic approach to cascade screening that may be co-ordinated in the community by nurse practitioners or by a centralised service 5 ; both strategies need further testing. To detect the majority of FH in the community requires more than cascade testing, however. 15 Universal screening strategies in childhood coupled with reverse cascade testing, using cholesterol and genetic testing, could meet the shortfall in detection. 16, 17 However, they require rigorous design and evaluation before implementation.
Diagnostic tools
Whilst the Dutch Lipid Clinic Network, Simon Broome and MED-PED criteria are the most popular tools for diagnosing FH, 5 their concordance and use in clinical practice is suboptimal. 18 In our practice, discordance rates of up to 20% and 40% may be seen for definite and probable diagnoses of FH, respectively, mandating a more robust and universally accepted diagnostic definition of FH. This is especially relevant when comparing the diagnosis of FH across populations. 19 Using genetic testing offers a solution, but has cost implications. The diagnostic criteria for homozygous FH are also problematic, 9 noting the recently published overlap between plasma LDL cholesterol levels and the presence of dual mutations affecting the LDL receptor pathway. 20 A recent consensus proposed a phenotypic approach whereby heterozygous and homozygous FH could pragmatically be bundled into a 'severe' diagnosis if LDL cholesterol levels were greater than 10.0 mmol/L alone, greater than 8.0 mmol/L with one high-risk characteristic, or greater than 5.0 mmol/L with two high-risk characteristics. 21 This operational definition has some value, but falls short of precision medicine.
Genetic testing
The practice of precision medicine in the care of FH classically involves the use of genetic testing. 22 Several papers have now confirmed that the prevalence of FH is at least 1:250 based on genetic testing alone. 8, 23, 24 The presence of a pathogenic mutation may also signify an increased risk of coronary artery disease across a wide spectrum of plasma LDL cholesterol concentrations. 23 This underscores the importance of LDL cholesterol life years and burden of atherosclerosis, 19 which is higher in FH than multigenic hypercholesterolaemia. 25 The latter may be suspected in the presence of, socalled, high 'cholesterol allelic scores' that reflect the sum of variants in genes (e.g. SORT1, APOB, LDLR, ABCG8, APOE) that collectively elevate plasma LDL cholesterol. Cholesterol gene scores may be useful to decide whether further sequencing is required when a suspected monogenic defect has not been identified and to bypass cascade testing when a diagnosis of multigenic hypercholesterolaemia alone is made. 26 Gene scores are fundamentally country-specific and their use cannot be extrapolated from published data in unrelated populations. The presence of a pathogenic mutation in the absence of phenotypic FH also remains a paradoxical outcome of cascade screening, 19 which is likely to involve the impact of 'protective' genes. 27 These gene variants may be useful in refining risk assessment, but rigorous standards for their classification, reporting and risk notification are required. 27 In the era of next-generation sequencing, new frameworks for genetic counselling of families with FH are also essential. 28 
Risk stratification: equations and imaging
The clinical expression of FH is variable. Methods for risk stratification have been well described. 2 Genetic deletions or rearrangements in the LDL receptor may signify a poorer prognosis and response to therapy. Elevated lipoprotein(a) [Lp(a)] consistently predicts cardiovascular risk in genetically defined FH. 29 Risk prediction models have been described, the most significant of which is from the SAFEHEART study, in which the equation employs obesity, hypertension, smoking, LDL cholesterol, Lp(a) and prior history of atherosclerotic cardiovascular disease to predict events with a Harrell C index of 0.85. 30 This model requires verification in other sample populations, however. Imaging of pre-clinical atherosclerosis, in particular cardiac computed tomographic (CT) scanning, may be the most valuable tool for assessing risk in FH. 31 Coronary CT angiography integrates the impact of cholesterol life years and can guide therapy, improve patient compliance and triage further cardiac investigations. 32 
Targets and treatments
Therapeutic targets and novel therapies for FH were well reviewed by Pec´in et al. 2 In light of recent clinical trials, 33, 34 revised therapeutic targets for atherogenic lipoproteins have been proposed, 35, 36 but reaching these targets remains a challenge in FH. The use of PCSK9 inhibitors relies on extrapolations from the FOURIER 34 and GLAGOV 37 trials, but neither selected patients for having FH. The biggest hurdle in care is access due to the high cost of these agents. Two analyses from Europe attest to the cost-effectiveness of these monoclonal antibodies in high-risk patients, including FH. [38] [39] [40] Valuable recommendations on how to overcome access barriers to PCSK9 inhibitors have recently been published. 41 Effective treatment of FH children with statins will involve addressing major gaps in current paediatric practice. 42 The optimal management of FH in pregnancy also needs further investigation. 43, 44 Organization of care: patient networks All models of care for FH have to be designed according to the available resources. 5 Services need integration across a continuum of care, and should include cardiology, paediatrics, genetics, imaging and transfusion medicine, with support from allied health personnel experienced in nursing, dietetics, psychology and pharmacy. Patient support groups and networks are essential for advocating improvement in care. This is particularly relevant at a time of access barriers to new therapies. 41 The value of such groups are well emphasized by activities of the US FH Foundation 45 and the European FH Patient Network. 46 
Codification and registries
Registries are important not only to raise awareness of FH, but also to garner information necessary for clinical trials, audits and health service research. 47, 48 Central to this is precise codification of FH, which is primarily based on the WHO ICD-10 system, but can vary between countries. 49 Recent registry data emphasize the marked shortfall in treatment of adults 50 and children 51 with FH in developed countries.
Research agenda
Since models of care require modification as new evidence accrues, an ongoing research program to focus efforts on critical issues is essential. 5 This was well emphasized in a recent AHA scientific statement which identified research nodes relating to basic science, population science, life course, clinical research, patient-centric research and evolving paradigms of care. 4 The prevention of cardiovascular disease through modification of high-risk disorders that alter lipid metabolism extend beyond FH. Accordingly, attention should also be given to other inherited atherogenic dyslipidaemias, including elevated Lp(a) and familial combined hyperlipidaemia, both of which can mimic FH 52 and merit their own models of care.
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